Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from July 10, 2026

Partial Published before the outcome was known, scored automatically when the window closed on October 8, 2026 — -20.8% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$45.63 – $47.28Entry zone — fair-value band

$48.23Published — price the day we called it

$52.39Target — the price the thesis aimed for

$51.46Peak — highest point inside the window, not a realized return

$38.18Window close — end-of-window price, context only

What happened

Partial

Reached 67% of the predicted growth at its peak, without hitting the target.

At window close

-20.8%

realized, from the publication price to the last close inside the window

Peak gain

+6.7%

peak, from the publication price — not a realized return

S&P 500, same window

+2.8%

SPY over the identical days, dividend-adjusted

Window close

$38.18

last close inside the window, ended October 8, 2026

Peak price

$51.46

peak on July 29, 2026 — not a realized return

Days to target

—

The thesis — published July 10, 2026

Predicted growth

+10%

over the measurement window

Target price

$52.39

the price the thesis aimed for

Entry zone

$45.63 – $47.28

the fair-value band we waited for

Price at publication

$48.23

published July 10, 2026

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk looks like a relatively safe healthcare company with a strong franchise in diabetes and obesity medicines. A recent label change for Wegovy makes the product more relevant, but overall earnings have been mixed and the consensus price target is below today's stock price. Competition, borrowing, price pressure, and supply issues limit confidence even as market interest improves. This makes a short-term recovery plausible, but not certain.

Primary drivers

Wegovy label change keeps the franchise relevant and visible
Long-term need for diabetes and obesity care stays strong
Valuation leaves room for price recovery if execution improves
Competition, debt levels, and pricing limit conviction near-term

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals